Australian company, Vaxine Pty Ltd, has developed a protein based COVID-19 vaccine that completely blocks virus transmission to non-immune individuals. The COVAX-19™ vaccine being developed by Australian company, Vaxine Pty Ltd, is set to be a game-changer in the fight against the COVID-19 pandemic and could allow earlier re-opening of national borders after it was shown to not only protect but also to completely block virus transmission to non-immune animals.
Vaxine’s biggest challenge now is to quickly raise the financial resources to complete Phase 3 human clinical trials and get Covid-19 vaccine manufactured at large scale which is likely to be in the order of $50 million dollars.
In another major breakthrough, Vaxine have also successfully created a breakthrough multivalent vaccine to protect against the new Covid-19 virus variants including the worrying South African, Brazilian and Indian mutant strains. The results of this multivalent Covid-19 vaccine formulation in animal testing is looking very promising.
Vaxine’s COVAX-19™ vaccine is a subunit vaccine based on synthetic protein produced using harmless insect cells to which Vaxine’s proprietary Advax polysaccharide adjuvant is added as a vaccine turbocharger to maximise the vaccine’s effectiveness and durability.
Vaxine is currently working with partners in overseas countries to assist in the upcoming phase 3 human clinical trials.
Vaxine has a long history of successfully developing pandemic vaccines, having previously developed vaccines against the SARS 3 and MERS coronaviruses that were shown to be highly protective in relevant animal models.
AstraZeneca and MSD’s Lynparza (olaparib) has shown efficacy in preventing cancer recurrence in patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.
Ammonia saved the world once; it might do it again. A century ago, the world faced a looming food crisis. A booming population was pushing farmers to grow crops faster than nitrogen-fixing bacteria in the soil could keep up, and the South American deposits of guano and natural nitrates they applied as fertilizer were dwindling.
Lipids are an unsung component in the two mRNA-based shots, the only vaccines to be approved so far in the US. Naked mRNA quickly degrades in the body and can trigger an unwanted immune reaction. To get the genetic material to its target cells, vaccine developers combine it with a mixture of several sophisticated lipids to form lipid nanoparticles, or LNPs. mRNA vaccine producers use a package of 4 lipids to formulate their LNPs
An unprecedented push to manufacture billions of doses this year alone has led to supply bottlenecks, putting firms such as Pfizer and AstraZeneca Plc in the firing line of angry government customers. Now the industry is taking heat for closely guarding its intellectual property.
If one positive could be drawn out of the devastating global COVID 19 crisis, it is the fact that this calamitous pandemic has made people more conscious about the need for healthier lifestyles, nutrition as well as their environmental footprint.
India’s devastating Covid-19 crisis is threatening operations at some of its biggest ports, raising concerns. The action could trigger shipping delays that reverberate through global supply chains.
A team of driven, concerned, caring citizens who decided to make a difference!
Over the last year, several drugs have either been developed or tested to treat coronavirus. Now there’s another new antiviral drug that’s showing some promise by demonstrating ability to stop SARS-CoV-2 transmission within 24 hour!
Looking within a short-term horizon, the outlook for container shipping over the next 2-3 months appears relatively well-known, although certainly not well-liked by shippers. In essence, we will continue to see a situation of bottleneck problems, capacity shortages and high pressure on rates. This is, hopefully, not a surprise to anyone now.